Pivotal phase 3 trial of RPL-554
Phase of Trial: Phase III
Latest Information Update: 13 Jan 2020
Price : $35 *
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Verona Pharma
- 13 Jan 2020 According to a Verona Pharma media release, the company plans to start this study in the third quarter of 2020.
- 09 Apr 2019 According to a Verona Pharma media release, the company will start this study in 2020.
- 14 Aug 2018 New trial record